Shaun S Ho1, Catherine Wall2, Richard B Gearry2, Jacqueline Keenan3, Andrew S Day1. 1. Department of Paediatrics, University of Otago Christchurch, Christchurch, New Zealand. 2. Department of Medicine, University of Otago Christchurch, Christchurch, New Zealand. 3. Department of Surgery, University of Otago Christchurch, Christchurch, New Zealand.
Abstract
INTRODUCTION: Although collecting faeces and blood samples are considered non-invasive methods of monitoring Crohn's disease (CD), these methods are less preferred by some patients. This study utilized urine as an alternative to evaluate four disease biomarkers in young adults with active CD before and after exclusive enteral nutrition (EEN) therapy. METHODS: Urine samples collected at baseline (W0) and after 8 weeks (W8) of EEN therapy were assayed by ELISA for levels of intestinal fatty acid-binding protein (I-FABP), liver fatty acid-binding protein (L-FABP), claudin-3, and calprotectin. Levels of each biomarker were also compared with standard clinical parameters, including disease indexes, nutrient, and inflammatory markers. RESULTS: Of the paired urine samples from 14 patients, 10 were female and 12 were newly diagnosed with CD. Urinary I-FABP: Cr (standardized to urine Cr) levels were significantly reduced, while urinary L-FABP: Cr levels increased following EEN therapy. Urinary L-FABP: Cr correlated positively with serum insulin-like growth factor 1 (IGF-1) (r = 0.60, p = 0.02). Urinary CLND3: Cr and calprotectin: Cr levels were not significantly different after treatment. CONCLUSION: I-FABP is a potential urinary biomarker of disease activity in adults with CD, while urinary L-FABP may be an indirect marker of nutritional status in adults with CD. CLND3 and calprotectin do not appear to have roles as urinary biomarkers in CD. These findings warrant further investigations using a larger sample size.
INTRODUCTION: Although collecting faeces and blood samples are considered non-invasive methods of monitoring Crohn's disease (CD), these methods are less preferred by some patients. This study utilized urine as an alternative to evaluate four disease biomarkers in young adults with active CD before and after exclusive enteral nutrition (EEN) therapy. METHODS: Urine samples collected at baseline (W0) and after 8 weeks (W8) of EEN therapy were assayed by ELISA for levels of intestinal fatty acid-binding protein (I-FABP), liver fatty acid-binding protein (L-FABP), claudin-3, and calprotectin. Levels of each biomarker were also compared with standard clinical parameters, including disease indexes, nutrient, and inflammatory markers. RESULTS: Of the paired urine samples from 14 patients, 10 were female and 12 were newly diagnosed with CD. Urinary I-FABP: Cr (standardized to urine Cr) levels were significantly reduced, while urinary L-FABP: Cr levels increased following EEN therapy. Urinary L-FABP: Cr correlated positively with serum insulin-like growth factor 1 (IGF-1) (r = 0.60, p = 0.02). Urinary CLND3: Cr and calprotectin: Cr levels were not significantly different after treatment. CONCLUSION: I-FABP is a potential urinary biomarker of disease activity in adults with CD, while urinary L-FABP may be an indirect marker of nutritional status in adults with CD. CLND3 and calprotectin do not appear to have roles as urinary biomarkers in CD. These findings warrant further investigations using a larger sample size.
Authors: Kaushik Bannerjee; Cecilia Camacho-Hübner; Katarzyna Babinska; Kay M Dryhurst; Ray Edwards; Martin O Savage; Ian R Sanderson; Nicholas M Croft Journal: J Pediatr Gastroenterol Nutr Date: 2004-03 Impact factor: 2.839
Authors: Maurice M A L Pelsers; Zbigniew Namiot; Wojciech Kisielewski; Andrzej Namiot; Marcin Januszkiewicz; Wim T Hermens; Jan F C Glatz Journal: Clin Biochem Date: 2003-10 Impact factor: 3.281
Authors: Anke L Lameris; Sylvie Huybers; Katri Kaukinen; Tuula H Mäkelä; René J Bindels; Joost G Hoenderop; Pasi I Nevalainen Journal: Scand J Gastroenterol Date: 2012-12-03 Impact factor: 2.423
Authors: M-A Meuwis; G Vernier-Massouille; J C Grimaud; Y Bouhnik; D Laharie; E Piver; L Seidel; J F Colombel; E Louis Journal: J Crohns Colitis Date: 2013-07-09 Impact factor: 9.071
Authors: Marcel C G van de Poll; Joep P M Derikx; Wim A Buurman; Wilbert H M Peters; Hennie M J Roelofs; Stephen J Wigmore; Cornelis Hc Dejong Journal: World J Surg Date: 2007-10 Impact factor: 3.352
Authors: Marta Gallego-Paüls; Carles Hernández-Ferrer; Mariona Bustamante; Xavier Basagaña; Jose Barrera-Gómez; Chung-Ho E Lau; Alexandros P Siskos; Marta Vives-Usano; Carlos Ruiz-Arenas; John Wright; Remy Slama; Barbara Heude; Maribel Casas; Regina Grazuleviciene; Leda Chatzi; Eva Borràs; Eduard Sabidó; Ángel Carracedo; Xavier Estivill; Jose Urquiza; Muireann Coen; Hector C Keun; Juan R González; Martine Vrijheid; Léa Maitre Journal: BMC Med Date: 2021-07-22 Impact factor: 8.775